BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are clonal stem cell disorders defined by proliferation of one or more myeloid lineages, and carry an increased risk of vascular events and progression to myelofibrosis and leukemia. Portal hypertension (pHTN) occurs in 7-18% of MPN patients via both thrombotic and nonthrombotic mechanisms and portends a poor prognosis.
| I N T R O D U C T I O N
BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), are clonal stem cell disorders defined by proliferation of one or more myeloid lineages, and carry an increased risk of vascular events and variable progression to myelofibrosis and acute leukemia. 1 Over the last decade, MPNs have been increasingly characterized by distinct driver mutations that correlate with clinical features and confer prognostic significance. The JAK2V617F mutation occurs in 95% of PV and 50-60% of ET and PMF patients, [2] [3] [4] [5] and acquired mutations within CALR and MPL genes account for majority of JAK2-negative ET and PMF. [6] [7] [8] Intriguingly, multiple studies have consistently demonstrated a prominent role of JAK2 V617F in vascular risk generally and MPN-associated portal hypertension specifically, although the underlying pathobiologic basis is not well understood. 11, 21 Portal hypertension (pHTN) occurs in 7-18% of MPN patients and portends a poor prognosis. [9] [10] [11] The etiologies of pHTN in MPN involve both thrombotic and nonthrombotic mechanisms. The most common cause of MPN-associated pHTN is splanchnic vein thrombosis (SVT), which includes Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT), mesenteric vein thrombosis, and splenic vein thrombosis. Extramedullary hematopoiesis (EMH) within the liver and spleen, a common feature of MPN, results in increased sinusoidal resistance and pressure within the portal circulation. 11, 12 Lastly, nodular regenerative hyperplasia (NRH), an under-recognized entity characterized by regenerative nodules in the absence of fibrosis, has been described in MPN patients with pHTN. 13 MPN-associated pHTN commonly presents with ascites, gastrointestinal varices, and, rarely, acute liver failure. 11 In contrast to cirrhotic pHTN, hepatic synthetic function is typically preserved in MPNassociated pHTN 13, 14 ; however, this population similarly is at risk for refractory ascites and gastrointestinal bleeding. 11 
| Study outcomes
The primary study outcomes were clinical resolution of pHTN, rate of 
| Statistical analysis
Patient characteristics, clinical outcomes, and post-TIPS complications were analyzed and represented as percentages of the entire cohort or as incidence rates over the follow-up period. All continuous variables were reported as medians and ranges.
| R E S U L T S 3.1 | Clinical characteristics
Twenty-nine patients met eligibility criteria and were included in the study. The median age was 47 years (range 27-86) and 65.5%
were women (Table 1) . PV and PV-MF were the most common MPN subtypes (70.0%), followed by PMF (10.3%), ET (10.3%), and isolated JAK2V617F or CALR mutations in one patient each.
Of note, three patients originally diagnosed with ET were subsequently identified as having PV prior to TIPS; additionally, another patient with isolated JAK2V617F mutation progressed to overt PV four years after TIPS. JAK2V617F mutation was present in 89.7% of patients, while CALR and MPL mutations were detected in one patient each.
BCS represented the predominant etiology of pHTN in 72.4% of patients; notably, two thirds of these patients were women with PV. 
| Efficacy of TIPS for MPN-associated pHTN
All patients demonstrated immediate reduction of portal pressures following TIPS insertion with a goal HVPG of less than 10-12 mmHg.
The majority of patients experienced complete resolution of ascites (96.2%) and varices (93.3%) after TIPS ( 
| Complications
Sixty-nine percent of patients experienced TIPS-related complications (Table 3) . TIPS dysfunction occurred in 37.9% of evaluable patients over 
| DISCUSSION
Our study represents the largest cohort to date of MPN patients treated with TIPS for medically refractory pHTN due to both thrombotic and nonthrombotic causes. TIPS procedure demonstrated substantial clinical efficacy, primary patency rates, and overall survival in our MPN cohort: including resolution of ascites and/or varices in over 90% of patients, primary 1-year patency rate of 89%, and three-year overall survival greater than 85%. We also observed that TIPS is associated with a high rate of manageable complications that must be weighed against the intended clinical benefit.
The widespread adoption of PTFE-covered stents has greatly improved long-term TIPS patency rates compared to traditional bare metal stents. 15 However, TIPS dysfunction remains the most significant long-term complication of the procedure. 22 Compared to cirrhotic patients, idiopathic BCS patients (40-50% MPN prevalence) have a higher incidence of TIPS dysfunction (42 vs. 13%), presumably due to the systemic hypercoaguable state of MPN. [23] [24] [25] [26] In a study of BCS patients, MPN diagnosis was an independent risk factor of TIPS dysfunction 30 ; however, a larger study found that TIPS dysfunction occurred in 41% of patients with no difference in outcomes for patients with or without MPN. 16 In our study, the overall incidence of TIPS dysfunction was 37.9% and data from a single center demonstrated 1-and 2-year primary patency rates with PFTE-covered stents of 89% and 78%, respectively. The primary TIPS patency rate in our study was higher than previous studies of BCS patient with reported 1-year patency rates between 56% and 80% with PTFE-coated stents. 27, 28 While the utility of TIPS has been established in BCS, there is little published data of TIPS used for nonthrombotic pHTN. 19, 24, 25 Previously, a small case series of 24 patients with NRH demonstrated clinical resolution of variceal bleeding and ascites in ten patients who underwent TIPS, 29 and another case series reported successful TIPS in two patients with PMF and EMH. 19, 30 Our results contribute to the literature and suggest a promising role of TIPS for nonthrombotic etiologies of MPN-associated pHTN.
Overall survival following TIPS was high in our group, with one, two, and three-year overall survival post-TIPS of 96.4%, 92.5%, and 85.2%, respectively. This closely mirrors the findings of a recent systematic review that found BCS-TIPS patients had a 1-year cumulative survival rate of 80-100% and a 5-year cumulative of 74-78%. 31 Of note, the incidence of hepatic encephalopathy in our cohort was low;
this may reflect greater intact hepatic synthetic function compared to cirrhotic patients receiving TIPS. The long-term survival of these patients underscores the need to longitudinally monitor for TIPS dysfunction and determine optimal prevention and management of complications.
Currently, indefinite anticoagulation is recommended for MPN patients who receive TIPS to prevent recurrent thrombotic events given the systemic hypercoagulability of the disease. 25 Despite a strong correlation, the specific mechanism underlying the JAK2V617F mutation and development of MPN-associated pHTN is not known. One possible explanation is that JAK2 mutations are acquired in a pluripotent stem cell with the capacity to contribute to hematopoietic and endothelial lineages, which may contribute to thrombogenicity; this is supported by patient samples demonstrating the presence of JAK2V617F mutation in hepatic endothelial cell progenitors. 36, 37 Intriguingly, while PV is highly associated with SVT, one study found that the risk of recurrent thrombosis was independent of MPN subtype or JAK2V617F mutation positivity. 32 Other less common MPN driver mutations, such as CALR, MPL, and JAK2 exon 12 have not exhibited a consistent correlation with SVT 35, 38, 39 ; however, one patient in our cohort had an isolated CALR mutation and BCS, indicating a tight but incomplete correlation between JAK2V617F and MPN-associated pHTN. Lastly, the incidence of HIT in our cohort was surprisingly high (20.7%), and HIT occurring in MPN patients has rarely been reported. 40, 41 It is unclear why our rate of HIT was high, and this potential association should be explored in future studies given the relevant implications for long-term anticoagulation in this population.
Limitations of our study are the relatively small cohort size and the retrospective nature of the analysis. However, our study focuses on a subset of patients with rare hematologic neoplasms, and our results reflect the longitudinal experience of three academic centers over the last two decades. Future multicenter, prospective studies are needed to better characterize which subsets of MPN-associated pHTN are most likely to benefit from TIPS and to establish the optimal management of TIPS dysfunction in this population.
In conclusion, our results indicate that TIPS is a well-tolerated and effective treatment of MPN-associated pHTN regardless of MPN subtype or etiology of pHTN. The high incidence of TIPS thrombosis in patients with PV and BCS supports long-term anticoagulation and close clinical monitoring for evidence of TIPS dysfunction.
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